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ABSTRACT
Objectives. A planned interim analysis of study
EGF100151 prompted early termination of enrollment
basedonalongertimetoprogressionwithlapatiniband
capecitabine than with capecitabine alone in patients
with human epidermal growth factor receptor
(HER)-2
previouslytreatedadvancedbreastcanceror
metastatic breast cancer (MBC). Here, we report final
analyses of overall survival.
Patients and Methods. Women with HER-2
 MBC
who progressed after regimens that included, but were
not limited to, anthracyclines, taxanes, and trastu-
zumab, were randomized to lapatinib (1,250 mg/day)
plus capecitabine (2,000 mg/m
2) or capecitabine mono-
therapy (2,500 mg/m
2) on days 1–14 of a 21-day cycle.
Results. At enrollment termination, 399 patients were
randomized, and nine were being screened and were of-
fered combination treatment. In total, 207 and 201 pa-
tients were enrolled to combination therapy and
monotherapy, respectively. Thirty-six patients receiving
monotherapycrossedovertocombinationtherapyfollow-
ing enrollment termination. The median overall survival
times were 75.0 weeks for the combination arm and 64.7
weeks for the monotherapy arm (hazard ratio [HR], 0.87;
95% confidence interval [CI], 0.71–1.08; p.210). A Cox
regressionanalysisconsideringcrossoverasatime-depen-
dent covariate suggested a 20% lower risk for death for
patientstreatedwithcombinationtherapy(HR,0.80;95%
CI, 0.64–0.99; p  .043). The low incidence of serious ad-
verseeventswasconsistentwithpreviouslyreportedrates.
Conclusions. Although premature enrollment termina-
tion and subsequent crossover resulted in insufficient
powertodetectdifferencesinoverallsurvival,exploratory
analysesdemonstrateatrendtowardasurvivaladvantage
with lapatinib plus capecitabine. These data continue to
support the efficacy of lapatinib in patients with HER-2

MBC. The Oncologist 2010;15:924–934
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Increased expression and activation of human epidermal
growth factor receptors (HERs) in breast cancer is associated
with a higher risk for disease recurrence and poor prognosis
[1].HER-2isoverexpressedin15%–20%ofnewlydiagnosed
breastcancercases[1].Theanti–HER-2monoclonalantibody
trastuzumab has led to a longer time to progression (TTP) and
overallsurvival(OS)timewhenaddedtochemotherapyinthe
first-line treatment of metastatic HER-2
 breast cancer pa-
tients, and it produces longer disease-free survival and OS
times when administered with or following chemotherapy in
the adjuvant setting [2–6]. However, resistance to trastu-
zumab is present or eventually develops in patients with met-
astatic disease, and recurrences following trastuzumab-based
adjuvant therapy still occur [7].
Lapatinib (Tykerb or Tyverb; GlaxoSmithKline, Re-
search Triangle Park, NC) is a small-molecule, reversible ty-
rosine kinase inhibitor (TKI) of epidermal growth factor
receptor and HER-2 [8]. A planned interim analysis of a ran-
domized, open-label, phase III trial (EGF100151) in women
with HER-2
, locally advanced breast cancer or metastatic
breast cancer (MBC) who progressed following treatment
with an anthracycline, a taxane, and trastuzumab in the adju-
vant or metastatic setting demonstrated that the addition of
lapatinib to capecitabine led to a significantly longer
independently assessed TTP. Based on that analysis, the inde-
pendent data monitoring committee (IDMC) recommended
early termination of enrollment, notification of the patients of
theresults,andofferingcombinationtreatmenttopatientsran-
domizedtomonotherapy.Efficacyandsafetydatafromthein-
terimanalysiswerereportedatthetimeaccrualwasclosedand
a subsequent analysis of data through the termination of ac-
crualwasreportedin2008[9,10].Intheupdatedanalysis,the
hazard ratio (HR) for TTP, the primary endpoint, was 0.57
(95% confidence interval [CI], 0.43–0.77; p  .001) [10]. At
that time, analysis of OS was immature, with 55 reported
deaths in the combination arm and 64 deaths in the mono-
therapy arm (HR, 0.78; 95% CI, 0.55–1.12; p  .177) [10].
We now present mature survival analyses as well as explor-
atoryanalysesadjustedforbaselineanddiseasehistoryparam-
eters and adjusted for crossover.
PATIENTS AND METHODS
The study design, eligibility criteria, treatment plan, and
statistical analyses have been detailed in prior publications
but are summarized here [9, 10]. The institutional review
board at each participating institution approved the study
protocol, and all enrolled patients provided written in-
formed consent.
Patient Eligibility
The study enrolled women with HER-2
 locally advanced
breastcancerorMBCwhohadprogressedaftertreatmentwith
regimens that included, but were not limited to, an anthracy-
cline, a taxane, and trastuzumab [9]. Criteria for HER-2 posi-
tivity were a score of 3 on the immunohistochemical (IHC)
analysis or 2 IHC staining intensity with demonstration of
geneamplificationbyfluorescenceinsituhybridizationasde-
termined by the local institution [9]. All patients had to have
measurablediseaseaccordingtotheResponseEvaluationCri-
teria in Solid Tumors (version 1.0) [11].
Treatment Plan
Patients were randomized 1:1 to treatment with lapatinib
(1,250 mg) daily plus capecitabine (2,000 mg/m
2 in two di-
videddoses)ondays1–14ofa21-daycycleorcapecitabine
monotherapy (2,500 mg/m
2 in two divided doses) on the
same cycle. The primary endpoint was independent assess-
ment of TTP (defined as time from randomization to dis-
ease progression or death resulting from breast cancer).
Secondary endpoints included progression-free survival
(PFS) (the time from randomization to disease progression
ordeathresultingfromanycause),OS,theoverallresponse
rate, the clinical benefit rate (confirmed complete response
plus confirmed partial response plus stable disease lasting
6months),andsafetymeasuredaccordingtotheNational
Cancer Institute’s Common Terminology Criteria for Ad-
verse Events (NCI CTCAE, version 3.0) [9].
Statistical Analysis
Enrollment was stopped on April 3, 2006, based on a recom-
mendationbytheIDMC[10].Priorpublicationshavedetailed
the sample size calculations, planned interim analysis, and
stopping rules [9, 10]. This report provides updated survival
analyses of all women (n  399) who underwent randomiza-
tion (intent-to-treat [ITT] population). In an effort to use data
from all treated patients, the nine patients who were in screen-
ing when the study was halted were included in analyses con-
ductedtoexplorebaselineprognosticfactorsandtheeffectsof
crossover on overall survival (n  408). Log-rank tests strati-
fiedbystageofdiseaseandpresenceorabsenceofvisceraldis-
ease were used to analyze time-to-event endpoints, and
Fisher’s exact tests were used for tumor response rates. All p-
values were calculated as two sided.
To explore the effect of baseline disease history and prog-
nostic factors on OS, a Cox proportional hazard model was
employed. The 11 baseline and disease history factors that
were investigated have been correlated with survival and are
considered to be prognostic in the management of patients
with MBC [12]. These factors were Eastern Cooperative On-
cology Group (ECOG) performance status score (0 or 1),
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or nonvisceral), liver metastases (yes or no), stage of disease
(IIIB/IIIC or IV), hormone receptor status (estrogen receptor
negative and progesterone receptor negative, estrogen recep-
tor positive, or progesterone receptor positive), time from last
dose of prior trastuzumab to randomization (8 weeks or 8
weeks), number of prior chemotherapy regimens (3o r3),
age,timefromdiagnosistorandomization,andtimefrommet-
astatic diagnosis to randomization.
A stepwise model-building approach was employed to
evaluate the effects of these baseline prognostic factors.
Treatment was retained in the model, whereas the prognos-
tic factors identified as significant in univariate models
were evaluated using stringent criteria for inclusion using
entry/exit criteria of  0.05.
RESULTS
Patient Population
WhenenrollmenttothestudyceasedonApril3,2006,there
had been 399 patients randomized (ITT population) plus a
further nine patients eligible who had not yet started treat-
ment. Following unblinding of the results, these nine pa-
tients were all treated with the combination and their
outcomes were not different from those patients random-
ized to the combination arm. Table 1 lists the patient base-
line prognostic factors. The groups were balanced for all
prognosticfactors.AsofOctober1,2008,340(83%)ofthe
408 patients had died. In the lapatinib plus capecitabine
treatment arm, 168 (81%) of 207 patients had died, seven
(3%) were censored when follow-up ended, and 32 (15%)
were censored with ongoing follow-up. In the capecitabine
monotherapy arm, 172 (86%) of 201 patients had died,
seven (3%) were censored when follow-up ended, and 22
(11%) were censored with ongoing follow-up.
Efficacy
OS
The median OS times in the ITT population were 75.0
weeksforthosetreatedwithlapatinibpluscapecitabineand
64.7 weeks for those treated with capecitabine alone, with
anHRof0.87(95%CI,0.70–1.08;p.206)(Fig.1A).An
analysis of OS that included the nine additional patients in
screening (n  408) yielded identical results (75.0 weeks
for combination therapy and 64.7 weeks for monotherapy,
with an HR of 0.87; 95% CI, 0.71–1.08; p  .210).
A Cox regression model, using data from all 408 en-
rolled patients, evaluated the effects of treatment group
along with baseline disease history and prognostic factors,
described in Patients and Methods, on OS. Univariate anal-
yses were conducted to evaluate prognostic factors in the
presence of treatment. Significant factors were then ana-
lyzed in a stepwise fashion. Final model results are pre-
sented in Table 2. The adjusted HR of 0.81 (95% CI, 0.65–
1.00; p  .051) represents a 19% lower risk for death for
patients treated with lapatinib plus capecitabine than for
thosetreatedwithcapecitabinealone.Theadjustedsurvival
curves considering these main treatment effects show that
the survival benefit was maintained over time in the com-
bination arm (Fig. 1B).
Effect of Crossover Therapy
When enrollment for the study was halted, 39 patients were
receiving capecitabine monotherapy. Of these, 35 patients
(90%) crossed over to combination therapy. An additional
patient who had discontinued capecitabine because of dis-
ease progression 6 days prior to the time enrollment was
halted also received combination therapy. As a result, a to-
tal of 36 patients crossed over to the combination arm,
thereby confounding the effect of treatment on OS. The
baseline prognostic factors for patients who crossed over to
lapatinib plus capecitabine were similar to those of the 165
patients on capecitabine alone who did not cross over. Be-
cause there is no optimal methodology to adjust for cross-
over in a survival analysis, several approaches were used to
conduct exploratory analyses.
Exclusion of crossover patients from the analysis resulted
in median OS times of 75.0 weeks in the combination group
and56.4weeksinthemonotherapygroup,withanHRof0.78
(95% CI, 0.62–0.97; p  .023) (Fig. 2). Although this ap-
proach discounts the benefit these patients may have received
from capecitabine alone, it also excludes any benefit these pa-
tients may have received from combination therapy.
Censoring patients at the time of crossover to the com-
binationarmresultedinmedianOStimesof75.0weeksfor
lapatinibpluscapecitabineand62.6weeksforcapecitabine
monotherapy, with an HR of 0.82 (95% CI, 0.66–1.02; p 
.074). This analysis reflects the benefit these patients re-
ceived from capecitabine monotherapy; however, it is a
conservative analysis and potentially favors the capecitab-
ine arm as a result of the fact that patients who died after
crossover were censored.
A Cox regression model considering crossover as a time-
dependent covariate was used to adjust for the effect of cross-
overwithoutexcludingtheeffectofcapecitabineonOSforthe
patients who crossed over. The Cox regression with time-
dependent crossover accounts for the effect of capecitabine as
well as the effect of the combination following crossover.
When crossover was used as a time-dependent covariate, the
HRforthecrossovereffectwas0.63(95%CI,0.41–0.98;p
.042), suggesting that patients’ risk for death was lower with
926 Lapatinib Plus Capecitabine Survival Analysiscrossover to lapatinib plus capecitabine. The HR for the treat-
ment effect (n  408) was 0.80 (95% CI, 0.64–0.99; p 
.043),suggestingaclinicallyrelevant20%lowerriskfordeath
for patients in the combination arm.
A final Cox regression model considered crossover as a
time-dependent covariate and included the baseline prog-
nostic factors identified as significant in the previous Cox
regression analysis (i.e., ECOG performance status score,
presenceorabsenceoflivermetastases,andnumberofmet-
astatic sites). The model demonstrated an HR of 0.75 (95%
CI, 0.60–0.94; p  .013) for the combination relative to
monotherapy, suggesting a survival benefit (Table 3). Fig-
ure 3 provides a forest plot of the various exploratory anal-
yses for OS adjusted for crossover. The results are
consistent, regardless of the model, and are consistent with
some attenuation of a demonstrable OS benefit resulting
from the effects of crossover.
Exploratory Analyses of the Impact of Prior
Trastuzumab Regimens on Efficacy
A previous analysis demonstrated that efficacy was not in-
fluenced by the interval from the last dose of trastuzumab
Table 1. Patient baseline prognostic factors
Baseline prognostic factor
Patients, n (%)
Lapatinib 
capecitabine
(n  207)
Capecitabine
monotherapy
(n  201)
Median age, yrs (range) 54 (26–80) 51 (28–83)
Disease site
Visceral 153 (74) 158 (79)
Nonvisceral 54 (26) 43 (21)
ECOG performance status score
0 127 (61) 117 (58)
1 79 (38) 77 (38)
Missing 1 (1) 7 (3)
Median time from initial diagnosis, yrs (range) 3.8 (0–21) 4.1 (0–19)
Median time from diagnosis of metastasis, yrs (range) 1.7 (0–9) 1.6 (0–8)
Metastatic sites
3 104 (50) 105 (52)
3 103 (50) 96 (48)
Liver metastases at baseline
Yes 111 (54) 102 (51)
No 96 (46) 99 (49)
Disease stage
IIIB/IIIC 8 (4) 8 (4)
IV 199 (96) 193 (96)
Hormone receptor status
ER
 and PR
 101 (49) 101 (50)
ER
 or PR
 99 (48) 93 (46)
Unknown 7 (3) 7 (3)
Prior chemotherapy regimens
3 31 (15) 37 (18)
3 176 (85) 164 (82)
Time from last dose of trastuzumab to randomization
8 wks 122 (59) 117 (58)
8 wks 83 (40) 77 (38)
Missing 2 (1) 7 (3)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PR, progesterone receptor.
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determine if the number of prior metastatic trastuzumab-
based regimens, regardless of the number of other prior
treatment regimens, might influence TTP and OS. Explor-
atory subgroup analyses of TTP and OS data are presented
for subgroups of patients treated with one or more than
one prior regimen containing trastuzumab for metastatic
disease.
Figure1. Kaplan–Meierestimatesofoverallsurvival(OS).(A):Intention-to-treatpopulation.(B):OScurveadjustedforEastern
Cooperative Oncology Group performance status score, number of metastatic sites, and liver metastases.
Table 2. Summary of Cox regression model for OS (n  408)
Covariate Effect tested HR (95% CI)
a p-value
Treatment group Lapatinib  capecitabine versus capecitabine 0.81 (0.65–1.00) .051
Metastatic sites 3 versus 3 0.64 (0.51–0.79) .001
ECOG performance status score 0 versus 1 0.56 (0.45–0.70) .001
Liver metastases No versus yes 0.52 (0.41–0.65) .001
aHR 1 indicates a lower risk.
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall
survival.
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based regimen, the median TTP were 31.3 weeks in the
combination arm and 18.6 weeks in the monotherapy arm
(HR, 0.50; 95% CI, 0.34–0.72; p  .001) (Fig. 4A). The
median OS times in this group were 71.4 weeks and 56.6
weeks (HR, 0.79; 95% CI, 0.60–1.03; p  .077). A trend
for a longer TTP was seen in patients who had been treated
with more than one metastatic trastuzumab-based regimen,
withmedianTTPof24.4weeksand19.7weeksinthecom-
bination and monotherapy arms, respectively (HR, 0.64;
95% CI, 0.38–1.07; p  .09) (Fig. 4B). However, in this
group, the median OS times were similar in both the com-
bination (77.1 weeks) and monotherapy (80.9 weeks) arms
(HR, 1.09; 95% CI, 0.74–1.60; p  .669).
Update on Severe Adverse Events
As of the data cutoff of October 1, 2008, a total of 115 se-
vere adverse events (SAEs) had been reported from 58 pa-
tients enrolled, including 47 events from 24 patients treated
withlapatinibpluscapecitabine,11eventsfromsixpatients
following crossover to combination therapy, and 57 events
from 28 patients treated with capecitabine monotherapy
(Table 4). The most frequently reported SAEs were diar-
rhea, dehydration, and vomiting.
Twelve deaths resulted from SAEs. In the combination
arm, four patients died as a result of the following SAEs as
assessed by the investigators: cardiorespiratory arrest,
lymphedema, hyponatremia, and general deterioration in
physical health. Two additional patients died from events
that were later determined to be related to disease progres-
sionandcentralnervoussystemmetastases,respectively.In
the capecitabine arm, six patients died from the following
nine SAEs (two patients experienced more than one fatal
SAE) as assessed by the investigators: diarrhea, vomiting,
cardiacarrest,intestinalobstruction,neutropenia,thrombo-
cytopenia, pulmonary embolism, dyspnea, and respiratory
arrest.
Cardiac Safety
A total of 11 patients experienced 12 events of decreased
left ventricular ejection fraction (LVEF). Eight patients
(mean age, 56 years; range, 46–68 years), four in each
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Figure 2. Kaplan–Meier estimates of overall survival including and excluding the crossover.
Table 3. Summary of Cox regression model for OS considering prognostic factors and crossover (N408)
Covariate Effect tested HR (95% CI)
a p-value
Treatment group Lapatinib  capecitabine versus capecitabine 0.75 (0.60–0.94) .013
ECOG performance status score 0 versus 1 0.55 (0.44–0.69) .001
Liver metastases No versus yes 0.52 (0.42–0.65) .001
Metastatic sites 3 versus 3 0.64 (0.51–0.80) .001
Time-dependent crossover Crossover versus not crossed over 0.65 (0.41–1.01) .054
aHR 1 indicates a lower risk.
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall
survival.
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(NCI CTCAE, version 3.0, grade 3 or 4 left ventricular sys-
tolic dysfunction or 20% absolute decrease in LVEF rel-
ative to the baseline value and below the institution’s lower
limit of normal). However, all eight patients were reported
as asymptomatic. Of note, one crossover patient experi-
enced two LVEF decrease events (once per treatment arm),
but was asymptomatic during both episodes. Among the
eight patients whose LVEF decrease met the protocol def-
inition, the mean time to onset of decrease in LVEF was 63
days, with a range of 21–201 days, and the mean nadir ab-
solutedeclineinLVEFwas26%relativetobaseline,witha
range of 20%–39%. LVEF effects in these patients were
complicated by previous use of cardiotoxic medications
(anthracyclines and trastuzumab) or concurrent conditions,
suchashypertension,leftchestradiation,andcardiopulmo-
nary diseases.
Hepatobiliary Events
Oral TKIs have been associated with a low risk for hepatic
toxicity as a possible class effect. Four patients (1.9%) in
the lapatinib plus capecitabine arm and three patients
(1.6%) in the capecitabine alone arm developed serious
hepatobiliary events, with one capecitabine patient having
two events. The hepatobiliary SAE reports were con-
founded by underlying medical conditions: worsening of
pre-existing liver metastasis, alternative diagnoses (e.g.,
bile duct obstruction), and concomitant medications asso-
ciated with hepatobiliary SAEs.
DISCUSSION
The EGF100151 study was originally designed with a
planned enrollment of 528 patients to provide 90% statisti-
cal power to detect a 50% longer TTP and 80% statistical
powertodetecta30%longerOStime.TheOSanalysiswas
to be performed after 457 deaths had occurred. When the
interim analysis demonstrated a significantly longer TTP
(HR, 0.57; 95% CI, 0.43–0.77; p  .001) with the addition
of lapatinib to capecitabine, patient enrollment was halted
before the sample size of 528 patients was met. The 340
deaths in the final analyses provided only a 68% power to
detect a 30% longer OS time. If crossover patients derived
additional benefit with crossover to the combination treat-
ment,theabilitytodetectasignificantdifferenceinOSmay
havebeenfurtherhampered.Nevertheless,itisimportantto
evaluate differences in OS recognizing the limitations of
the analysis and to explore methods that attempt to address
the potential impact of crossover.
The mature survival analysis performed when 83% of
patients had died shows a trend for improvement with the
combination. Although these data suggest that the addition
of lapatinib to capecitabine led to a longer survival time,
furtherresearchisneededtoidentifypatientswhomayben-
efit the most from the addition of lapatinib to chemother-
apy. However, it would be difficult to gather more
information from the current study because of premature
stoppage of accrual to the trial, crossover effects, and the
effects of subsequent treatments on OS.
Figure 3. Hazard ratios and 95% confidence intervals for OS analyses.
Abbreviations: Adj, adjusted; OS, overall survival; w/, with; w/o, without.
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tory and treatment crossover were conducted using several
methodologies to adjust for crossover. Each of the methods
demonstrated a greater reduction in the HR for death than
that determined by the ITT analysis, suggesting that the
benefit from the combination following crossover from
monotherapy may have impacted the ability of the ITT
analysis to demonstrate a significant difference in the OS
times. These updated survival analyses support the demon-
strated efficacy of lapatinib in the TTP analysis in this
heavily pretreated population.
Exploratory analyses have also been conducted to deter-
mine whether the interval from the last dose of prior trastu-
zumab [10] and the number of prior trastuzumab-based
regimens would predict differential clinical benefit from lapa-
Table 4. Most frequently reported serious adverse events
(3 reports)
Adverse
event, n
Lapatinib 
capecitabine
(n  207)
Lapatinib 
capecitabine
crossover
patients
(n  36)
Capecitabine
monotherapy
(n  191)
Diarrhea 7 1 5
Dehydration 3 0 3
Vomiting 2 1 3
Dyspnea 3 0 1
Nausea 0 1 3
Figure 4. Kaplan–Meier estimates of time to progression in patients receiving: one prior metastatic trastuzumab-based regimen
(A) or more than one prior metastatic trastuzumab-based regimen (B).
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who did not benefit from the addition of lapatinib but sug-
gestedthatlapatinibmaybemoreeffectiveinpatientswhohad
received only one prior trastuzumab-containing regimen.
However,moreresearchisneededtoconfirmtheseresultsbe-
cause of the small number of patients in each subset.
TheincidencesofSAEsweresimilarinthecapecitabine
monotherapy and lapatinib plus capecitabine combination
arms.DiarrheawasthemostcommonSAEreportedforthis
study. Lapatinib did not appear to be associated with a
greater risk for key SAEs, including pneumonitis/pneumo-
nia, LVEF, and hepatobiliary events.
CONCLUSIONS
AninterimanalysisofEGF100151showedsignificantclinical
benefits, including a trend toward OS in favor of combination
therapy, versus monotherapy in patients with trastuzumab-
pretreated HER-2
 MBC. These results led to the premature
termination of accrual to the study, and patients receiving
monotherapy were permitted to cross over to combination
therapy. Although premature termination and crossover re-
sulted in insufficient power to detect an OS benefit, these up-
dated analyses confirm a trend toward an OS advantage in the
combination arm. A Cox regression analysis considering
crossover as a time-dependent covariate suggested that there
may have been a 20% lower risk for death in the combination
therapy arm. In addition, the incidences of SAEs were largely
consistent with previous reports [13, 14]. Overall, these up-
dated analyses continue to support the clinical benefit and
safety of lapatinib in patients with HER-2
 MBC.
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